Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06916143 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

StatusTerminated
PhasePhase 1
Started2025-04-08
View on ClinicalTrials.gov ↗
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.

Amendment history 5 changes detected by DataLookout

2026-09-10
Trial terminated: Original scientific question rendered moot by the external scientific community
2026-09-10
Final enrollment: 1 participants — 2% of the 48 planned
2026-09-10
Primary completion confirmed: April 2025 (last estimated August 2026)
2026-07-17
Primary completion pushed: 2026-07 → 2026-08
2026-07-17
Completion pushed: 2026-07 → 2026-08
Trial Details
NCT Number NCT06916143
Lead Sponsor Eli Lilly and Company
Conditions Healthy Participants
Enrollment 1 participants
Start Date 2025-04-08
Primary Completion 2025-04-08 (estimated)
Study Completion 2025-04-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-09